Merck KGaA Boosts 2025 Earnings on Semiconductor Growth, Faces Pharma Challenges
Merck KGaA’s 2025 review shows semiconductor growth driving earnings, while pharma faces sales pressure and new gene‑editing acquisition boosts life‑sciences revenue.
4 minutes to read









